New medical cannabis spray is coming to help treat skin conditions

467 0

Scientists have developed a novel way to get more benefits out of cannabis

Cannassure, a cannabis company based in Israel, just announced this week that it is working to develop a “topical cannabis spray” which should prove useful in the treatment of a variety of inflammatory skin conditions. Cannassure is working alongside the huge Swedish Pharmaceutical Company, Lipidor, which specializes in dermatology.

The two companies hooked up under a development agreement after successfully getting their products through the first feasibility stages. What they are developing is an over-the-counter (OTC) topical spray for the treatment of inflammatory skin conditions such as ‘atopic dermatitis,’ psoriasis, and well as for pain and lesions.

Cannassure has also acquired the exclusive rights to use Lipidor’s innovative AKVANO topical spray technology. The company estimates that the combined treatment market for all of these chronic illnesses and symptoms could find a value of well over $50 billion annually by the year 2027.

Ran Amir, CEO of Cannassure, has said that the company looked forward to the joint development process. “The AKVANO non-touch application is paired with an excellent uptake of active substance in different skin layers opens up the door for new high-potential treatments with great patient benefits. The merger depended on Cannassure scientists to prove that the cannabinoids can be well combined into the AKVANO system, into a homogeneous, uniform and stable formulation.

Ola Holmlund, the CEO of Lipidor AB, was “delighted” about the licensing agreement and emphasized the importance of the feasibility study’s results. “This is an important milestone and an external validation of our unique formulation platform, showing that cannabinoids can also be well incorporated into AKNANO.”